Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD8 regulatory T cell therapy in transplantation: a new path to clinical success?

Transplant international : official journal of the European Society for Organ Transplantation·2026

Same author

MUC4-targeted CAR-T Cells Restrain Chemotherapy-resistant Colorectal Cancer.

bioRxiv : the preprint server for biology·2026

Same author

Targeting PD-1<sup>+</sup> T cells with chimeric antigen receptors to reduce the HIV reservoir.

Science advances·2026

Same author

[Chlorhexidine and latex allergy : "hidden" allergens to keep in mind].

Revue medicale suisse·2026

Same author

Preformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026

Same author

Dual CD8 and TCR editing in regulatory T cells mediates HLA-A2-restricted tissue-specific homing.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026

Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026

Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026

Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026

Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026

Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 19, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Next-generation regulatory T cell therapy.

Leonardo M R Ferreira^1,2,3, Yannick D Muller¹, Jeffrey A Bluestone^4,5

¹Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.

Nature Reviews. Drug Discovery

|September 22, 2019

Summary

This summary is machine-generated.

Regulatory T (Treg) cells are crucial for immune balance. Enhancing Treg cell therapy using advanced technologies shows promise for treating autoimmune diseases and transplant rejection.

More Related Videos

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Experiment Videos

Last Updated: Jan 19, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Area of Science:

Immunology
Cell Therapy
Transplantation Science

Background:

Regulatory T (Treg) cells maintain immune homeostasis by suppressing excessive immune responses.
Defects in Treg cell function lead to autoimmune diseases and transplant complications.
Treg cells possess multiple mechanisms for immune suppression, making them potential therapeutics.

Purpose of the Study:

To review advances in Treg cell therapy for inflammatory disorders.
To explore the application of genetic engineering in enhancing Treg cell therapies.
To discuss the prospects of Treg cell-based treatments in autoimmunity and transplantation.

Main Methods:

Review of current literature on Treg cell biology and therapy.
Analysis of technological advancements in chimeric antigen receptor (CAR) development and genome editing (CRISPR-Cas9).
Evaluation of early-phase clinical trial data for Treg cell therapy.

Main Results:

Treg cell therapy has demonstrated feasibility, tolerability, and potential efficacy in clinical trials.
Genetic engineering technologies are being utilized to improve Treg cell specificity and function.
Significant progress has been made in optimizing T cell therapies for various conditions.

Conclusions:

Treg cell-based therapies offer a promising avenue for treating autoimmune diseases and preventing transplant rejection.
Advanced technologies like CARs and CRISPR-Cas9 are key to developing next-generation Treg cell therapies.
Further research and clinical development are essential to fully realize the therapeutic potential of Treg cells.